Eclectic Associates Inc. ADV Buys 268 Shares of Johnson &
Eclectic Associates Inc. ADV raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,626 shares of the company’s stock after acquiring an additional 268 shares during the quarter. Johnson & Johnson makes up approximately 1.1% of Eclectic Associates Inc. ADV’s investment portfolio, making the stock its 21st largest position. Eclectic Associates Inc. ADV’s holdings in Johnson & Johnson were worth $1,706,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Family CFO Inc acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. Steward Financial Group LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $34,000. Joseph P. Lucia & Associates LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $38,000. Advocacy Wealth Management Services LLC increased its stake in shares of Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after buying an additional 67 shares during the period. Finally, Iron Horse Wealth Management LLC increased its stake in shares of Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock valued at $45,000 after buying an additional 61 shares during the period. 68.78% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson stock opened at $178.14 on Wednesday. The stock has a market capitalization of $468.76 billion, a price-to-earnings ratio of 24.01, a PEG ratio of 3.55 and a beta of 0.63. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The stock’s 50 day moving average price is $177.11 and its two-hundred day moving average price is $173.88. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company had revenue of $23.43 billion for the quarter, compared to analysts’ expectations of $23.62 billion. During the same period last year, the business earned $2.59 EPS. Johnson & Johnson’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 10.23 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were issued a $1.13 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date was Monday, May 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.92%.
In related news, insider William Hait sold 29,699 shares of the stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total value of $5,452,142.42. Following the transaction, the insider now directly owns 80,236 shares in the company, valued at approximately $14,729,724.88. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. Over the last quarter, insiders sold 78,161 shares of company stock worth $13,895,302. 0.35% of the stock is owned by company insiders.
JNJ has been the subject of several recent research reports. Citigroup lowered their price objective on Johnson & Johnson from $210.00 to $205.00 in a research note on Tuesday, May 17th. Credit Suisse Group increased their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating for the company. The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Finally, Raymond James increased their target price on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $190.50.
Johnson & Johnson Company Profile (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
